FDA Approves Two Novo Nordisk Insulin Medications

In late September 2015, the FDA finally approved Tresiba, a diabetes drug from Novo Nordisk. This once daily medication is a long-acting  drug that was previously rejected in 2013 after the FDA requested more data about the heart risks  associated with Tresiba.

The medication is currently sold in 30 countries and is expected to launch in the U.S. in early 2016.

For the full article, please visit:

Diabetes Health in the News Podcast: FDA Approves Two Novo Nordisk Insulin Medications

Leave a Reply

Your email address will not be published. Required fields are marked *